Gulsun Akay, Ozge Karadag, Kahraman Gungor, Aylin Ekmekcioglu

The Awareness and Knowledge of Dentists of MedicationRelated Osteonecrosis of the Jaw

Objective: Medication-related osteonecrosis of the jaw (MRONJ) is a serious condition affecting the quality of life of patients taking antiresorptive and anti-angiogenic drugs. The main purpose of this study was to evaluate dentists’ awareness of MRONJ. Methods: A questionnaire was administered to dentists. The questionnaire contained 20 questions on the demographic data of the participants and their awareness of MRONJ and the complications of antiresorptive or anti-angiogenic drugs. The responses were analyzed using Pearson’s chi-square test and Fisher’s exact test. Results: In total, 141 dentists participated in the survey. Of these, 42.6% did not know about MRONJ. There was a statistically significant difference between specialist dentists and general dentists on the questions about the complications, effects, and usage of antiresorptive and anti-angiogenic drugs on necrosis formation (p

PDF

___

[1] Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 Update. Approved by the Board of Trustees January 2009. Aust Endod J 2009; 35(3):119-130.
[2] Gomez Font R, Martinez Garcia ML, Olmos Martinez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal 2008; 13(5):318-324.
[3] Raj DV, Abuzar M, Borromeo GL. Bisphosphonates, healthcare professionals and oral health. Gerodontology 2016; 33(1):135-143.
[4] Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014; 72(10):1938–1956.
[5] Crépin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaws induced by clodronate, an alkyl bisphosphonate: case report and literature review. Eur J Clin Pharmacol 2010; 66 (6):547-554.
[6] Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 2015; 43(2):290-293.
[7] Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J 2017; 222(2):121-125.
[8] Fleisher KE, Kontio R, Otto S. Antiresorptive drug-related osteonecrosis of the jaw (ARONJ)–a guide to research. Davos Platz (Switzerland): AO Foundation; Available at:
[9] Yazdi PM, Schiodt M. Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 119(4):416–422.
[10] Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018; 69:177–187.
[11] De Lima PB, Brasil VLM, Castro JFL, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer 2015; 23(12):3421-3426.
[12] Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43(6):847–854.
[13] Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E. Surgery-triggered and non-surgery triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011; 47(3):191–194.
[14] Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63(11): 1567-1575.
[15] Yoo JY, Park YD, Kwon YD, Kim DY, Ohe JY. Survey of Korean dentists on the awareness of bisphosphonate-related osteonecrosis of the jaws. J Investig Clin Dent 2010; 1(2):90–95.
[16] Vinitzky-Brener I, Ibáñez-Mancera NG, Aguilar-Rojas AM, Álvarez-Jardón AP. Knowledge of bisphosphonate-related osteonecrosis of the Jaws among Mexican dentists. Med Oral Patol Oral Cir Bucal 2017; 22(1):84-e7.
[17] López-Jornet P, Camacho-Alonso F, Molina – Miñano F, GomezGarcia F. Bisphosphonate associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract 2010; 16(5):878-882.
[18] Escobedo M, García-Consuegra L, Junquera S, Olay S, Ascani G, Junquera L. Medication-related osteonecrosis of the jaw: A survey of knowledge, attitudes, and practices among dentists in the principality of Asturias (Spain). J Stomatol Oral Maxillofac Surg 2018; 119(5):395-400.
[19] Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30(1):3–23.
[20] Sosa M, Go´mez de Tejada MJ, Baga´n JV, Diaz CM, Diez PA. Osteonecrosis of the jaws: consensus document. Rev Osteoporos Metab Miner 2009; 1(1):41–51.
[21] Fantasia JE. Bisphosphonates-what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 2009; 67(5 Suppl):53-60.
[22] Skjødt MK, Frost M, Abrahamsen B. Side effects of drugs for osteoporosis and metastatic bone disease. Br J Clin Pharmacol 2019; 85(6):1036-1071.
[23] Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg 2012; 40(3):277-282.